Breaking News
Investing Pro 0
Cyber Monday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER

Radiopharm Theranostics to present interim data and continues to validate work with brain cancer

Stock Markets Sep 21, 2022 12:30
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Radiopharm Theranostics to present interim data and continues to validate work with brain cancer

Radiopharm Theranostics Ltd (ASX:RAD) will present its interim data from Imperial College London’s F-18 Pivalate Phase 2a imaging trial in brain metastases, funded by the Medical Research Council, at the 34th EORTC/AACR/NCI symposium in Barcelona from October 26-28.

The data will also be published in a peer-reviewed journal.

Presentation of the data in both formats gives strong validation to the work the company is doing in the field of cancer diagnostics and therapeutics.

Promising theranostic approach

“We are very pleased to see a new molecule and an innovative mode of action in an area of high unmet medical need and we cannot wait to see the data presented,” Radiopharm’s CEO and managing director Riccardo Canevari said.

“The team at Imperial College London, led by Professor Aboagye, did a tremendous job. F18-Pivalate and its potential therapeutic variations, currently under development, represent a promising theranostic approach to target brain metastases and potentially other brain tumours.”

Professor Aboagye added: “We’re very excited to present our interim data soon. A potentially innovative and effective new imaging approach will be more than welcomed in this field.”

Hitting its milestones

RAD, developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, has also acquired an exclusive worldwide licence for the Pivalate platform technology from Cancer Research Technology Limited and Imperial College London, and has a Sponsored Research Agreement on new analogues with its inventor Professor Eric Aboagye.

And just yesterday, the company announced it entered into a clinical supply agreement with SHINE Technologies, a next-generation fusion technology company, which will see SHINE supply isotope non-carrier-added lutetium-177 (Lu-177) to help RAD develop its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products.

Read more: Radiopharm Theranostics enters supply agreement to strengthen clinical pipeline of radiopharmaceutical products

Read more on Proactive Investors AU

Disclaimer

Radiopharm Theranostics to present interim data and continues to validate work with brain cancer
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email